CRVS Corvus Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-09 16:00
Why CRVS matters now
Corvus Pharmaceuticals, Inc. (CRVS) is a US stock in Healthcare. The latest InvestLog snapshot shows $16.20 with +0.75% on the session and $1.36B in market capitalization; recent performance reads 1-month +3.57% and YTD +54.68%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-13.7M, and EPS of $-0.15. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.5%.
The latest indexable market news headline is "Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?" from The Motley Fool.
Additional event context on this page matters because analyst consensus is Buy with a median target of $31.00; recent insider activity includes van den Broek Richard filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.45
P/S
0.00
EV/EBITDA
-22.76
DCF Value
$0.02
FCF Yield
-3.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-38.9%
ROA
-17.4%
ROIC
-19.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-13.7M | $-0.15 |
| Q4 2025 | $0.00 | $-12.3M | $-0.18 |
| FY 2025 | $0.00 | $-15.3M | $-0.53 |
| Q3 2025 | $0.00 | $-10.2M | $-0.12 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$33.17
Target (Median)
$31.00
Target Range
$27.00 - $42.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.84
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.